{"entity":{"id":"nct05941507","kind":"trial","name":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of LCB84 in advanced solid tumours, run by LigaChem Biosciences, Inc., now recruiting.","summary":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors. ClinicalTrials.gov record last updated 2025-09-24: recruiting. Enrollment is planned at 300 participants. Primary completion is estimated at 2027-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: LCB84, Anti-PD-1 monoclonal antibody. Registered primary measures: Safety of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1 and 2); Recommended Phase 2 Dose of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1); Objective Response Rate (Phase 2).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05941507","url":"https://clinicaltrials.gov/study/NCT05941507"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["lcb84"],"companies":["ligachem-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2025-09-24: recruiting. Enrollment is planned at 300 participants. Primary completion is estimated at 2027-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT05941507","phase":"1/2","setting":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","sponsor":"LigaChem Biosciences, Inc.","participation":[{"nct":"NCT05941507","source":"https://clinicaltrials.gov/study/NCT05941507","fetchedAt":"2026-10-07T16:54:02.117Z","studySha256":"e1a87919ac2d6006e78d51e5219ce4bc40b17300d7dc560ae06c63a9cd7fc92d","overallStatus":"RECRUITING","lastUpdatePosted":"2025-09-24","leadSponsor":"LigaChem Biosciences, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":300,"enrolmentType":"ESTIMATED","siteCount":8,"recruitingSiteCount":6,"countries":["Canada","United States"]}],"started":"2023-10-05","startedType":"actual","enrolled":300,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05941507/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"lcb84","kind":"drug","name":"LCB84","route":"/drugs/lcb84/"}],"company":[{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","route":"/companies/ligachem-biosciences/"}]}}